Brian Cheng
Stock Analyst at JP Morgan
(1.02)
# 3,624
Out of 4,846 analysts
67
Total ratings
33.96%
Success rate
-21.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Neutral | $130 → $129 | $127.72 | +1.01% | 3 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.04 | -20.32% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $26.47 | +54.89% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $24.58 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $49.19 | +15.88% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $7.38 | +76.15% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.31 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.79 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $11.64 | +54.61% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $8.25 | +239.39% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $46 | $15.13 | +204.03% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $2.74 | +1,104.38% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.83 | +228.77% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $8.94 | +168.46% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.36 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.37 | +1,267.61% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.34 | +497.01% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.01 | +36.24% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.45 | +3,046.07% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.42 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.76 | +692.08% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.19 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.16 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $7.94 | +151.89% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $12.69 | +569.82% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $10.89 | +92.93% | 1 | Aug 3, 2021 |
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $130 → $129
Current: $127.72
Upside: +1.01%
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.04
Upside: -20.32%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $26.47
Upside: +54.89%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.58
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $49.19
Upside: +15.88%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $7.38
Upside: +76.15%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.31
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.79
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $11.64
Upside: +54.61%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.25
Upside: +239.39%
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $15.13
Upside: +204.03%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $2.74
Upside: +1,104.38%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.83
Upside: +228.77%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $8.94
Upside: +168.46%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.36
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.37
Upside: +1,267.61%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.34
Upside: +497.01%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.01
Upside: +36.24%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.45
Upside: +3,046.07%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.42
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.76
Upside: +692.08%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.19
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.16
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $7.94
Upside: +151.89%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $12.69
Upside: +569.82%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $10.89
Upside: +92.93%